nodes	percent_of_prediction	percent_of_DWPC	metapath
Pantoprazole—ABCG2—Teniposide—lymphatic system cancer	0.138	0.182	CbGbCtD
Pantoprazole—ABCG2—Mitoxantrone—lymphatic system cancer	0.0962	0.127	CbGbCtD
Pantoprazole—CYP1A2—Carmustine—lymphatic system cancer	0.0844	0.112	CbGbCtD
Pantoprazole—ABCG2—Vincristine—lymphatic system cancer	0.0662	0.0876	CbGbCtD
Pantoprazole—CYP2C19—Teniposide—lymphatic system cancer	0.0615	0.0814	CbGbCtD
Pantoprazole—CYP2C9—Teniposide—lymphatic system cancer	0.0511	0.0676	CbGbCtD
Pantoprazole—SLCO1B1—Methotrexate—lymphatic system cancer	0.0504	0.0668	CbGbCtD
Pantoprazole—ABCG2—Methotrexate—lymphatic system cancer	0.0401	0.0531	CbGbCtD
Pantoprazole—ABCB1—Mitoxantrone—lymphatic system cancer	0.0347	0.0459	CbGbCtD
Pantoprazole—CYP3A4—Cytarabine—lymphatic system cancer	0.0302	0.0399	CbGbCtD
Pantoprazole—CYP3A4—Teniposide—lymphatic system cancer	0.0297	0.0393	CbGbCtD
Pantoprazole—ABCB1—Vincristine—lymphatic system cancer	0.0239	0.0316	CbGbCtD
Pantoprazole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0208	0.0275	CbGbCtD
Pantoprazole—ABCB1—Methotrexate—lymphatic system cancer	0.0144	0.0191	CbGbCtD
Pantoprazole—CYP3A4—Vincristine—lymphatic system cancer	0.0143	0.0189	CbGbCtD
Pantoprazole—Infection—Bleomycin—lymphatic system cancer	0.000287	0.00117	CcSEcCtD
Pantoprazole—Anaemia—Carmustine—lymphatic system cancer	0.000285	0.00117	CcSEcCtD
Pantoprazole—Back pain—Vincristine—lymphatic system cancer	0.000285	0.00117	CcSEcCtD
Pantoprazole—Vomiting—Teniposide—lymphatic system cancer	0.000285	0.00116	CcSEcCtD
Pantoprazole—Sepsis—Methotrexate—lymphatic system cancer	0.000284	0.00116	CcSEcCtD
Pantoprazole—Agitation—Carmustine—lymphatic system cancer	0.000284	0.00116	CcSEcCtD
Pantoprazole—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000283	0.00116	CcSEcCtD
Pantoprazole—Asthenia—Fludarabine—lymphatic system cancer	0.000283	0.00115	CcSEcCtD
Pantoprazole—Rash—Teniposide—lymphatic system cancer	0.000283	0.00115	CcSEcCtD
Pantoprazole—Dermatitis—Teniposide—lymphatic system cancer	0.000282	0.00115	CcSEcCtD
Pantoprazole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000281	0.00115	CcSEcCtD
Pantoprazole—Headache—Teniposide—lymphatic system cancer	0.000281	0.00115	CcSEcCtD
Pantoprazole—Pruritus—Fludarabine—lymphatic system cancer	0.000279	0.00114	CcSEcCtD
Pantoprazole—Back pain—Mitoxantrone—lymphatic system cancer	0.000278	0.00113	CcSEcCtD
Pantoprazole—Leukopenia—Carmustine—lymphatic system cancer	0.000276	0.00113	CcSEcCtD
Pantoprazole—Anorexia—Bleomycin—lymphatic system cancer	0.000275	0.00112	CcSEcCtD
Pantoprazole—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000274	0.00112	CcSEcCtD
Pantoprazole—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000273	0.00112	CcSEcCtD
Pantoprazole—Anaemia—Vincristine—lymphatic system cancer	0.000272	0.00111	CcSEcCtD
Pantoprazole—Agitation—Vincristine—lymphatic system cancer	0.000271	0.00111	CcSEcCtD
Pantoprazole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000271	0.00111	CcSEcCtD
Pantoprazole—Photosensitivity—Methotrexate—lymphatic system cancer	0.00027	0.00111	CcSEcCtD
Pantoprazole—Hypotension—Bleomycin—lymphatic system cancer	0.00027	0.0011	CcSEcCtD
Pantoprazole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000269	0.0011	CcSEcCtD
Pantoprazole—Convulsion—Carmustine—lymphatic system cancer	0.000268	0.00109	CcSEcCtD
Pantoprazole—Hypertension—Carmustine—lymphatic system cancer	0.000267	0.00109	CcSEcCtD
Pantoprazole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000266	0.00109	CcSEcCtD
Pantoprazole—Nausea—Teniposide—lymphatic system cancer	0.000266	0.00109	CcSEcCtD
Pantoprazole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000265	0.00108	CcSEcCtD
Pantoprazole—Vertigo—Vincristine—lymphatic system cancer	0.000265	0.00108	CcSEcCtD
Pantoprazole—Hepatic failure—Methotrexate—lymphatic system cancer	0.000264	0.00108	CcSEcCtD
Pantoprazole—Leukopenia—Vincristine—lymphatic system cancer	0.000264	0.00108	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000263	0.00107	CcSEcCtD
Pantoprazole—Myalgia—Carmustine—lymphatic system cancer	0.000263	0.00107	CcSEcCtD
Pantoprazole—Chest pain—Carmustine—lymphatic system cancer	0.000263	0.00107	CcSEcCtD
Pantoprazole—Anxiety—Carmustine—lymphatic system cancer	0.000262	0.00107	CcSEcCtD
Pantoprazole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000259	0.00106	CcSEcCtD
Pantoprazole—Malaise—Mitoxantrone—lymphatic system cancer	0.000259	0.00106	CcSEcCtD
Pantoprazole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000257	0.00105	CcSEcCtD
Pantoprazole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000257	0.00105	CcSEcCtD
Pantoprazole—Convulsion—Vincristine—lymphatic system cancer	0.000255	0.00104	CcSEcCtD
Pantoprazole—Hypertension—Vincristine—lymphatic system cancer	0.000255	0.00104	CcSEcCtD
Pantoprazole—Confusional state—Carmustine—lymphatic system cancer	0.000254	0.00104	CcSEcCtD
Pantoprazole—Oedema—Carmustine—lymphatic system cancer	0.000252	0.00103	CcSEcCtD
Pantoprazole—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000252	0.00103	CcSEcCtD
Pantoprazole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000251	0.00103	CcSEcCtD
Pantoprazole—Myalgia—Vincristine—lymphatic system cancer	0.000251	0.00103	CcSEcCtD
Pantoprazole—Visual disturbance—Methotrexate—lymphatic system cancer	0.000251	0.00102	CcSEcCtD
Pantoprazole—Cough—Mitoxantrone—lymphatic system cancer	0.000251	0.00102	CcSEcCtD
Pantoprazole—Infection—Carmustine—lymphatic system cancer	0.00025	0.00102	CcSEcCtD
Pantoprazole—Vomiting—Fludarabine—lymphatic system cancer	0.00025	0.00102	CcSEcCtD
Pantoprazole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000249	0.00102	CcSEcCtD
Pantoprazole—Rash—Fludarabine—lymphatic system cancer	0.000248	0.00101	CcSEcCtD
Pantoprazole—Dermatitis—Fludarabine—lymphatic system cancer	0.000248	0.00101	CcSEcCtD
Pantoprazole—Hypertension—Mitoxantrone—lymphatic system cancer	0.000248	0.00101	CcSEcCtD
Pantoprazole—Pain—Bleomycin—lymphatic system cancer	0.000247	0.00101	CcSEcCtD
Pantoprazole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000247	0.00101	CcSEcCtD
Pantoprazole—Headache—Fludarabine—lymphatic system cancer	0.000247	0.00101	CcSEcCtD
Pantoprazole—Tachycardia—Carmustine—lymphatic system cancer	0.000246	0.00101	CcSEcCtD
Pantoprazole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000244	0.000999	CcSEcCtD
Pantoprazole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000244	0.000999	CcSEcCtD
Pantoprazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000244	0.000999	CcSEcCtD
Pantoprazole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000244	0.000995	CcSEcCtD
Pantoprazole—Discomfort—Mitoxantrone—lymphatic system cancer	0.000241	0.000987	CcSEcCtD
Pantoprazole—Oedema—Vincristine—lymphatic system cancer	0.000241	0.000983	CcSEcCtD
Pantoprazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000241	0.000983	CcSEcCtD
Pantoprazole—Anorexia—Carmustine—lymphatic system cancer	0.00024	0.000982	CcSEcCtD
Pantoprazole—Infection—Vincristine—lymphatic system cancer	0.000239	0.000977	CcSEcCtD
Pantoprazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000238	0.000972	CcSEcCtD
Pantoprazole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000238	0.00097	CcSEcCtD
Pantoprazole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000236	0.000965	CcSEcCtD
Pantoprazole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000236	0.000964	CcSEcCtD
Pantoprazole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000236	0.000962	CcSEcCtD
Pantoprazole—Hypotension—Carmustine—lymphatic system cancer	0.000236	0.000962	CcSEcCtD
Pantoprazole—Oedema—Mitoxantrone—lymphatic system cancer	0.000234	0.000957	CcSEcCtD
Pantoprazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000234	0.000957	CcSEcCtD
Pantoprazole—Nausea—Fludarabine—lymphatic system cancer	0.000234	0.000956	CcSEcCtD
Pantoprazole—Infection—Mitoxantrone—lymphatic system cancer	0.000233	0.000951	CcSEcCtD
Pantoprazole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000233	0.00095	CcSEcCtD
Pantoprazole—Shock—Mitoxantrone—lymphatic system cancer	0.000231	0.000942	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00023	0.000938	CcSEcCtD
Pantoprazole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000229	0.000937	CcSEcCtD
Pantoprazole—Urticaria—Bleomycin—lymphatic system cancer	0.000229	0.000937	CcSEcCtD
Pantoprazole—Anorexia—Vincristine—lymphatic system cancer	0.000229	0.000937	CcSEcCtD
Pantoprazole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000229	0.000934	CcSEcCtD
Pantoprazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.000228	0.000933	CcSEcCtD
Pantoprazole—Insomnia—Carmustine—lymphatic system cancer	0.000228	0.000931	CcSEcCtD
Pantoprazole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000228	0.00093	CcSEcCtD
Pantoprazole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000227	0.000925	CcSEcCtD
Pantoprazole—Paraesthesia—Carmustine—lymphatic system cancer	0.000226	0.000925	CcSEcCtD
Pantoprazole—Mood swings—Methotrexate—lymphatic system cancer	0.000225	0.000919	CcSEcCtD
Pantoprazole—Hypotension—Vincristine—lymphatic system cancer	0.000225	0.000919	CcSEcCtD
Pantoprazole—Dyspnoea—Carmustine—lymphatic system cancer	0.000225	0.000918	CcSEcCtD
Pantoprazole—Somnolence—Carmustine—lymphatic system cancer	0.000224	0.000915	CcSEcCtD
Pantoprazole—Anorexia—Mitoxantrone—lymphatic system cancer	0.000223	0.000913	CcSEcCtD
Pantoprazole—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000219	0.000896	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000219	0.000896	CcSEcCtD
Pantoprazole—Decreased appetite—Carmustine—lymphatic system cancer	0.000219	0.000895	CcSEcCtD
Pantoprazole—Hypotension—Mitoxantrone—lymphatic system cancer	0.000219	0.000895	CcSEcCtD
Pantoprazole—Insomnia—Vincristine—lymphatic system cancer	0.000218	0.000889	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000218	0.000889	CcSEcCtD
Pantoprazole—Paraesthesia—Vincristine—lymphatic system cancer	0.000216	0.000883	CcSEcCtD
Pantoprazole—Constipation—Carmustine—lymphatic system cancer	0.000216	0.000881	CcSEcCtD
Pantoprazole—Pain—Carmustine—lymphatic system cancer	0.000216	0.000881	CcSEcCtD
Pantoprazole—Breast disorder—Methotrexate—lymphatic system cancer	0.000215	0.000877	CcSEcCtD
Pantoprazole—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000214	0.000874	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000213	0.000872	CcSEcCtD
Pantoprazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000213	0.000869	CcSEcCtD
Pantoprazole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00021	0.00086	CcSEcCtD
Pantoprazole—Decreased appetite—Vincristine—lymphatic system cancer	0.000209	0.000855	CcSEcCtD
Pantoprazole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000209	0.000854	CcSEcCtD
Pantoprazole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000208	0.000851	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000208	0.000849	CcSEcCtD
Pantoprazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.000208	0.000849	CcSEcCtD
Pantoprazole—Fatigue—Vincristine—lymphatic system cancer	0.000207	0.000848	CcSEcCtD
Pantoprazole—Asthenia—Bleomycin—lymphatic system cancer	0.000207	0.000846	CcSEcCtD
Pantoprazole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000206	0.000843	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000206	0.000842	CcSEcCtD
Pantoprazole—Pain—Vincristine—lymphatic system cancer	0.000206	0.000841	CcSEcCtD
Pantoprazole—Constipation—Vincristine—lymphatic system cancer	0.000206	0.000841	CcSEcCtD
Pantoprazole—Asthma—Methotrexate—lymphatic system cancer	0.000205	0.000839	CcSEcCtD
Pantoprazole—Pruritus—Bleomycin—lymphatic system cancer	0.000204	0.000835	CcSEcCtD
Pantoprazole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000204	0.000832	CcSEcCtD
Pantoprazole—Eosinophilia—Methotrexate—lymphatic system cancer	0.000203	0.00083	CcSEcCtD
Pantoprazole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000202	0.000825	CcSEcCtD
Pantoprazole—Pancreatitis—Methotrexate—lymphatic system cancer	0.000201	0.000822	CcSEcCtD
Pantoprazole—Constipation—Mitoxantrone—lymphatic system cancer	0.0002	0.000819	CcSEcCtD
Pantoprazole—Pain—Mitoxantrone—lymphatic system cancer	0.0002	0.000819	CcSEcCtD
Pantoprazole—Abdominal pain—Carmustine—lymphatic system cancer	0.000199	0.000814	CcSEcCtD
Pantoprazole—Body temperature increased—Carmustine—lymphatic system cancer	0.000199	0.000814	CcSEcCtD
Pantoprazole—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000197	0.000804	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000197	0.000804	CcSEcCtD
Pantoprazole—Pancytopenia—Methotrexate—lymphatic system cancer	0.000195	0.000797	CcSEcCtD
Pantoprazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000193	0.000789	CcSEcCtD
Pantoprazole—Dysuria—Methotrexate—lymphatic system cancer	0.000192	0.000784	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000192	0.000783	CcSEcCtD
Pantoprazole—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000191	0.00078	CcSEcCtD
Pantoprazole—Abdominal pain—Vincristine—lymphatic system cancer	0.00019	0.000777	CcSEcCtD
Pantoprazole—Body temperature increased—Vincristine—lymphatic system cancer	0.00019	0.000777	CcSEcCtD
Pantoprazole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000189	0.000773	CcSEcCtD
Pantoprazole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000187	0.000766	CcSEcCtD
Pantoprazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000186	0.000761	CcSEcCtD
Pantoprazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000186	0.000759	CcSEcCtD
Pantoprazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000185	0.000757	CcSEcCtD
Pantoprazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000185	0.000757	CcSEcCtD
Pantoprazole—Pneumonia—Methotrexate—lymphatic system cancer	0.000184	0.000752	CcSEcCtD
Pantoprazole—Vomiting—Bleomycin—lymphatic system cancer	0.000184	0.00075	CcSEcCtD
Pantoprazole—Infestation—Methotrexate—lymphatic system cancer	0.000183	0.000748	CcSEcCtD
Pantoprazole—Infestation NOS—Methotrexate—lymphatic system cancer	0.000183	0.000748	CcSEcCtD
Pantoprazole—Depression—Methotrexate—lymphatic system cancer	0.000183	0.000746	CcSEcCtD
Pantoprazole—Rash—Bleomycin—lymphatic system cancer	0.000182	0.000744	CcSEcCtD
Pantoprazole—Dermatitis—Bleomycin—lymphatic system cancer	0.000182	0.000743	CcSEcCtD
Pantoprazole—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000181	0.000741	CcSEcCtD
Pantoprazole—Asthenia—Carmustine—lymphatic system cancer	0.000181	0.000739	CcSEcCtD
Pantoprazole—Stomatitis—Methotrexate—lymphatic system cancer	0.000178	0.000729	CcSEcCtD
Pantoprazole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000178	0.000727	CcSEcCtD
Pantoprazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000177	0.000724	CcSEcCtD
Pantoprazole—Sweating—Methotrexate—lymphatic system cancer	0.000175	0.000717	CcSEcCtD
Pantoprazole—Haematuria—Methotrexate—lymphatic system cancer	0.000175	0.000713	CcSEcCtD
Pantoprazole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000173	0.000707	CcSEcCtD
Pantoprazole—Epistaxis—Methotrexate—lymphatic system cancer	0.000173	0.000705	CcSEcCtD
Pantoprazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000173	0.000705	CcSEcCtD
Pantoprazole—Asthenia—Vincristine—lymphatic system cancer	0.000173	0.000705	CcSEcCtD
Pantoprazole—Diarrhoea—Carmustine—lymphatic system cancer	0.000172	0.000705	CcSEcCtD
Pantoprazole—Nausea—Bleomycin—lymphatic system cancer	0.000172	0.000701	CcSEcCtD
Pantoprazole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000171	0.000698	CcSEcCtD
Pantoprazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000168	0.000687	CcSEcCtD
Pantoprazole—Dizziness—Carmustine—lymphatic system cancer	0.000167	0.000681	CcSEcCtD
Pantoprazole—Haemoglobin—Methotrexate—lymphatic system cancer	0.000165	0.000675	CcSEcCtD
Pantoprazole—Diarrhoea—Vincristine—lymphatic system cancer	0.000165	0.000673	CcSEcCtD
Pantoprazole—Hepatitis—Methotrexate—lymphatic system cancer	0.000164	0.000671	CcSEcCtD
Pantoprazole—Haemorrhage—Methotrexate—lymphatic system cancer	0.000164	0.000671	CcSEcCtD
Pantoprazole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000163	0.000666	CcSEcCtD
Pantoprazole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000162	0.000663	CcSEcCtD
Pantoprazole—Urethral disorder—Methotrexate—lymphatic system cancer	0.000161	0.000658	CcSEcCtD
Pantoprazole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00016	0.000655	CcSEcCtD
Pantoprazole—Vomiting—Carmustine—lymphatic system cancer	0.00016	0.000655	CcSEcCtD
Pantoprazole—Dizziness—Vincristine—lymphatic system cancer	0.000159	0.00065	CcSEcCtD
Pantoprazole—Rash—Carmustine—lymphatic system cancer	0.000159	0.000649	CcSEcCtD
Pantoprazole—Dermatitis—Carmustine—lymphatic system cancer	0.000159	0.000649	CcSEcCtD
Pantoprazole—Visual impairment—Methotrexate—lymphatic system cancer	0.000158	0.000647	CcSEcCtD
Pantoprazole—Headache—Carmustine—lymphatic system cancer	0.000158	0.000645	CcSEcCtD
Pantoprazole—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000155	0.000635	CcSEcCtD
Pantoprazole—Eye disorder—Methotrexate—lymphatic system cancer	0.000154	0.000627	CcSEcCtD
Pantoprazole—Tinnitus—Methotrexate—lymphatic system cancer	0.000153	0.000626	CcSEcCtD
Pantoprazole—Vomiting—Vincristine—lymphatic system cancer	0.000153	0.000625	CcSEcCtD
Pantoprazole—Rash—Vincristine—lymphatic system cancer	0.000152	0.00062	CcSEcCtD
Pantoprazole—Dermatitis—Vincristine—lymphatic system cancer	0.000152	0.000619	CcSEcCtD
Pantoprazole—Headache—Vincristine—lymphatic system cancer	0.000151	0.000616	CcSEcCtD
Pantoprazole—Nausea—Carmustine—lymphatic system cancer	0.00015	0.000612	CcSEcCtD
Pantoprazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000149	0.000609	CcSEcCtD
Pantoprazole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000148	0.000606	CcSEcCtD
Pantoprazole—Rash—Mitoxantrone—lymphatic system cancer	0.000148	0.000604	CcSEcCtD
Pantoprazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000148	0.000603	CcSEcCtD
Pantoprazole—Chills—Methotrexate—lymphatic system cancer	0.000147	0.000602	CcSEcCtD
Pantoprazole—Headache—Mitoxantrone—lymphatic system cancer	0.000147	0.0006	CcSEcCtD
Pantoprazole—Alopecia—Methotrexate—lymphatic system cancer	0.000145	0.000593	CcSEcCtD
Pantoprazole—Mental disorder—Methotrexate—lymphatic system cancer	0.000144	0.000588	CcSEcCtD
Pantoprazole—Malnutrition—Methotrexate—lymphatic system cancer	0.000143	0.000584	CcSEcCtD
Pantoprazole—Nausea—Vincristine—lymphatic system cancer	0.000143	0.000584	CcSEcCtD
Pantoprazole—Dysgeusia—Methotrexate—lymphatic system cancer	0.00014	0.000572	CcSEcCtD
Pantoprazole—Nausea—Mitoxantrone—lymphatic system cancer	0.000139	0.000569	CcSEcCtD
Pantoprazole—Back pain—Methotrexate—lymphatic system cancer	0.000138	0.000565	CcSEcCtD
Pantoprazole—Vision blurred—Methotrexate—lymphatic system cancer	0.000135	0.000551	CcSEcCtD
Pantoprazole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000133	0.000542	CcSEcCtD
Pantoprazole—Anaemia—Methotrexate—lymphatic system cancer	0.000132	0.00054	CcSEcCtD
Pantoprazole—Malaise—Methotrexate—lymphatic system cancer	0.000129	0.000527	CcSEcCtD
Pantoprazole—Vertigo—Methotrexate—lymphatic system cancer	0.000129	0.000525	CcSEcCtD
Pantoprazole—Leukopenia—Methotrexate—lymphatic system cancer	0.000128	0.000523	CcSEcCtD
Pantoprazole—Cough—Methotrexate—lymphatic system cancer	0.000125	0.00051	CcSEcCtD
Pantoprazole—Convulsion—Methotrexate—lymphatic system cancer	0.000124	0.000506	CcSEcCtD
Pantoprazole—Myalgia—Methotrexate—lymphatic system cancer	0.000122	0.000498	CcSEcCtD
Pantoprazole—Arthralgia—Methotrexate—lymphatic system cancer	0.000122	0.000498	CcSEcCtD
Pantoprazole—Chest pain—Methotrexate—lymphatic system cancer	0.000122	0.000498	CcSEcCtD
Pantoprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000121	0.000494	CcSEcCtD
Pantoprazole—Discomfort—Methotrexate—lymphatic system cancer	0.00012	0.000492	CcSEcCtD
Pantoprazole—Confusional state—Methotrexate—lymphatic system cancer	0.000118	0.000481	CcSEcCtD
Pantoprazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000117	0.000477	CcSEcCtD
Pantoprazole—Infection—Methotrexate—lymphatic system cancer	0.000116	0.000474	CcSEcCtD
Pantoprazole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000114	0.000468	CcSEcCtD
Pantoprazole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000114	0.000467	CcSEcCtD
Pantoprazole—Skin disorder—Methotrexate—lymphatic system cancer	0.000113	0.000463	CcSEcCtD
Pantoprazole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000113	0.000461	CcSEcCtD
Pantoprazole—Anorexia—Methotrexate—lymphatic system cancer	0.000111	0.000455	CcSEcCtD
Pantoprazole—Hypotension—Methotrexate—lymphatic system cancer	0.000109	0.000446	CcSEcCtD
Pantoprazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000106	0.000435	CcSEcCtD
Pantoprazole—Insomnia—Methotrexate—lymphatic system cancer	0.000106	0.000431	CcSEcCtD
Pantoprazole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000105	0.000428	CcSEcCtD
Pantoprazole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000104	0.000425	CcSEcCtD
Pantoprazole—Somnolence—Methotrexate—lymphatic system cancer	0.000104	0.000424	CcSEcCtD
Pantoprazole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000103	0.00042	CcSEcCtD
Pantoprazole—Decreased appetite—Methotrexate—lymphatic system cancer	0.000101	0.000415	CcSEcCtD
Pantoprazole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000101	0.000412	CcSEcCtD
Pantoprazole—Fatigue—Methotrexate—lymphatic system cancer	0.000101	0.000411	CcSEcCtD
Pantoprazole—Pain—Methotrexate—lymphatic system cancer	9.98e-05	0.000408	CcSEcCtD
Pantoprazole—Feeling abnormal—Methotrexate—lymphatic system cancer	9.62e-05	0.000393	CcSEcCtD
Pantoprazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	9.55e-05	0.00039	CcSEcCtD
Pantoprazole—Urticaria—Methotrexate—lymphatic system cancer	9.27e-05	0.000379	CcSEcCtD
Pantoprazole—Abdominal pain—Methotrexate—lymphatic system cancer	9.23e-05	0.000377	CcSEcCtD
Pantoprazole—Body temperature increased—Methotrexate—lymphatic system cancer	9.23e-05	0.000377	CcSEcCtD
Pantoprazole—Hypersensitivity—Methotrexate—lymphatic system cancer	8.6e-05	0.000351	CcSEcCtD
Pantoprazole—Asthenia—Methotrexate—lymphatic system cancer	8.38e-05	0.000342	CcSEcCtD
Pantoprazole—Pruritus—Methotrexate—lymphatic system cancer	8.26e-05	0.000337	CcSEcCtD
Pantoprazole—Diarrhoea—Methotrexate—lymphatic system cancer	7.99e-05	0.000326	CcSEcCtD
Pantoprazole—Dizziness—Methotrexate—lymphatic system cancer	7.72e-05	0.000315	CcSEcCtD
Pantoprazole—Vomiting—Methotrexate—lymphatic system cancer	7.42e-05	0.000303	CcSEcCtD
Pantoprazole—Rash—Methotrexate—lymphatic system cancer	7.36e-05	0.000301	CcSEcCtD
Pantoprazole—Dermatitis—Methotrexate—lymphatic system cancer	7.35e-05	0.0003	CcSEcCtD
Pantoprazole—Headache—Methotrexate—lymphatic system cancer	7.31e-05	0.000299	CcSEcCtD
Pantoprazole—Nausea—Methotrexate—lymphatic system cancer	6.93e-05	0.000283	CcSEcCtD
